Literature DB >> 24005834

Oncogenic herpesvirus HHV-8 promotes androgen-independent prostate cancer growth.

Justin G Mygatt1, Adit Singhal, Gauthaman Sukumar, Clifton L Dalgard, Johnan A R Kaleeba.   

Abstract

Mechanisms underlying progression to androgen-independent prostate cancer following radical ablation therapy remain poorly defined. Although intraprostatic infections have been highlighted as potential cofactors, pathogen influences on pathways that support tumor regrowth are not known. To explore this provocative concept, we derived androgen-sensitive and -insensitive prostate epithelial cells persistently infected with human herpesvirus 8 (HHV-8), an oncogenic herpesvirus that has been detected in normal prostate epithelium, prostate adenocarcinoma, and biologic fluids of patients with prostate cancer, to explore its effects on transition to hormone-refractory disease. Strikingly, we found that HHV-8 infection of androgen-sensitive prostate cancer cells conferred the capacity for androgen-independent growth. This effect was associated with altered expression and transcriptional activity of the androgen receptor (AR). However, HHV-8 infection bypassed AR signaling by promoting enhancer of zeste homolog 2 (EZH2)-mediated epigenetic silencing of tumor-suppressor genes, including MSMB and DAB2IP that are often inactivated in advanced disease. Furthermore, we found that HHV-8 triggered epithelial-to-mesenchymal transition. Although HHV-8 has not been linked etiologically to prostate cancer, virologic outcomes revealed by our study provide mechanistic insight into how intraprostatic infections could constitute risk for progression to androgen-independent metastatic disease where EZH2 has been implicated. Taken together, our findings prompt further evaluations of the relationship between HHV-8 infections and risk of advanced prostate cancer. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24005834     DOI: 10.1158/0008-5472.CAN-12-4196

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  3 in total

1.  Prospective study of human herpesvirus type 8 serostatus and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention Trial.

Authors:  Siobhan Sutcliffe; Cathee Till; Frank J Jenkins; Charlotte A Gaydos; Phyllis J Goodman; Ashraful M Hoque; Ann W Hsing; Ian M Thompson; William G Nelson; Angelo M De Marzo; Elizabeth A Platz
Journal:  Cancer Causes Control       Date:  2014-10-31       Impact factor: 2.506

2.  Detection and characterization of latency stage of EBV and histopathological analysis of prostatic adenocarcinoma tissues.

Authors:  Khalid Ahmed; Alisalman Sheikh; Saira Fatima; Ghulam Haider; Kulsoom Ghias; Farhat Abbas; Nouman Mughal; Syed Hani Abidi
Journal:  Sci Rep       Date:  2022-06-21       Impact factor: 4.996

Review 3.  Molecular pathways and targets in prostate cancer.

Authors:  Emma Shtivelman; Tomasz M Beer; Christopher P Evans
Journal:  Oncotarget       Date:  2014-09-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.